Choice of first medication prescribed for overactive bladder changes with time: trends from the aua aqua registry

You have accessJournal of UrologyCME1 Apr 2023MP37-14 CHOICE OF FIRST MEDICATION PRESCRIBED FOR OVERACTIVE BLADDER CHANGES WITH TIME: TRENDS FROM THE AUA AQUA REGISTRY Camille Vélez, Max Bowman, Katherine Shapiro, Rachel Mbassa, Raymond Fang, Benjamin Brucker, and Michelle van Kuiken Camille VélezCamille Vélez More articles by this author , Max BowmanMax Bowman More articles by this author , Katherine ShapiroKatherine Shapiro More articles by this author , Rachel MbassaRachel Mbassa More articles by this author , Raymond FangRaymond Fang More articles by this author , Benjamin BruckerBenjamin Brucker More articles by this author , and Michelle van KuikenMichelle van Kuiken More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003275.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Overactive bladder (OAB) is a clinical condition that can greatly affect quality of life. Pharmacological management of OAB may involve use of anticholinergic (ACH) or beta-3 agonists (B3) medications; however, there is increasing evidence of cognitive side-effects associated with the long-term use of ACH medications. Using the AUA AQUA Registry, we aim to evaluate how prescription trends between ACH and B3 agonists has changed over time. METHODS: We queried the AUA Quality (AQUA) Registry database, a national Qualified Clinical Data Registry, for patients >18 years with a new diagnosis of OAB including urinary urgency, frequency, and urgency urinary incontinence (UUI) from 2014-2020 using ICD-9 and ICD-10 codes. Patients with a diagnosis of neurogenic bladder or neurologic diagnosis associated with neurogenic bladder were excluded. The choice of first medication prescribed for OAB was assessed and these trends were observed and analyzed. RESULTS: A total of 641,112 patients were diagnosed with OAB over the study period, 17.5% of whom received a medication prescription. In 2014, ACH comprised 76.3% of OAB treatment prescriptions, while B3 agonists made up 22.1%; Over time, ACH use steadily declined to only 60.3% of first prescriptions, while B3 agonist prescriptions nearly doubled to a peak of 41.4% in 2019, leveling off to 38% in 2020. (Figure 1a). When comparing individual ACH medications, a sharp decrease was observed in solifenacin prescriptions, which went from the most prescribed ACH at 34.8% in 2014 to third most prescribed at 7.7% in 2020. As solifenacin use declined, oxybutynin ER use increased from 11.9% in 2014 to a peak of 26.4% in 2020 to become the most prescribed ACH (Figure 1b). CONCLUSIONS: These prescription trends illustrate that ACH medications remain the most common class of medications first prescribed for OAB, however B3 agonist use has steadily increased with time. Further investigation leveraging the AUA AQUA Registry will help understand what drives OAB medication prescription trends by urologists in the US. Source of Funding: This study was supported by AUA statistical services © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e519 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Camille Vélez More articles by this author Max Bowman More articles by this author Katherine Shapiro More articles by this author Rachel Mbassa More articles by this author Raymond Fang More articles by this author Benjamin Brucker More articles by this author Michelle van Kuiken More articles by this author Expand All Advertisement PDF downloadLoading ...